Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P2Y6 shRNA is a short hairpin RNA designed to silence the expression of the P2Y purinoceptor 6 (P2Y6R), a G protein-coupled receptor that is activated by extracellular uridine diphosphate (UDP). In multiple myeloma (MM), P2Y6R is abnormally overexpressed and promotes tumor cell proliferation and survival through the Gαq/11-mediated calcium signaling pathway. By knocking down P2Y6R, this shRNA inhibits the elevation of intracellular Ca2+ levels, reduces the phosphorylation of CaMKIIγ, and suppresses the NF-κB signaling pathway. Preclinical studies conducted at Jiangxi Medical College have demonstrated that P2Y6 shRNA effectively inhibits the growth of myeloma cells in both in vitro and in vivo xenograft models, highlighting P2Y6R as a potential therapeutic target for the treatment of multiple myeloma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on P2Y6 shRNA.